A Novel Hematopoietic Adaptor Protein, Chat-H, Positively Regulates T Cell Receptor-mediated Interleukin-2 Production by Jurkat Cells*

Akira SakakibaraDagger §, Seisuke HattoriDagger ||**, Shun NakamuraDagger , and Takuya KatagiriDagger ||**

From the Dagger  Division of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan, the § Department of Cell Biology, University of Virginia, Charlottesville, Virginia 22908, and the || Division of Cellular Proteomics, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Received for publication, August 5, 2002, and in revised form, December 2, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chat (Cas/HEF1-associated signal transducer) is a novel adaptor protein with an N-terminal Src homology-2 domain and C-terminal Cas/HEF1 association domain. We report here the molecular cloning of Chat-H, the hematopoietic isoform of Chat. Chat-H has an extended N-terminal domain besides the known Chat domain structures, suggesting a unique function of Chat-H in hematopoietic cells. Jurkat transfectants overexpressing Chat-H show a marked increase in interleukin-2 production after costimulation of T cell receptor and CD28. The degree of JNK activation is enhanced substantially in the Chat-H transfectants upon costimulation. The Src homology-2 domain mutant of Chat-H loses this signal modulating activity. Expression of the Cas/HEF1 association domain mutant exhibits a dominant negative effect on both JNK activation and interleukin-2 production. We further found that Chat-H forms a complex with Pyk2H and enhances its tyrosine 402 phosphorylation, an up-regulator of the JNK pathway. These results suggest that Chat-H positively controls T cell function via integrating the costimulatory signals.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The antigen-induced activation of T cell receptor (TCR)1 triggers a variety of T cell responses such as cytokine production and cell proliferation, differentiation, adhesion, and migration (1-3). It has been well characterized that nonreceptor type tyrosine kinases including Lck, Fyn, and ZAP-70 play pivotal roles in initiating the TCR signals (4, 5). Several adaptor proteins that comprise various signaling modules mediating protein-protein or protein-lipid interactions relay the TCR-elicited signals to induce downstream immune responses (6-8). In addition to integrating extracellular signals, cell type-specific expression of the signaling molecules may be critical in determining the cell type-specific response to extracellular stimuli. SLP-76 and LAT are expressed exclusively in T cells and function as essential adaptor proteins in the TCR signaling. Besides the TCR-derived signals, costimulation signals elicited by engagement of coreceptors such as CD28 are crucial to induce sufficient immune responses (9). When TCR activation occurs in the absence of the costimulation signals, T cells become anergic, and these T cells never produce interleukin-2 (IL-2) upon restimulation of the TCR (10).

TCR-mediated signals activate members of the mitogen-activated protein kinase (MAPK) family (11-15). These kinases phosphorylate various transcription factors inducing the expression of several immune response-related genes. The MAPK subgroups include the extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and p38 MAPKs, which differ in their response and substrate specificities. In T cells, JNK and p38 MAPK are synergistically activated by costimulation of TCR and CD28 auxiliary receptors. By contrast, no synergy is observed in the ERK activation. Efficient induction of IL-2 synthesis appears to require the activation of these three distinct MAPKs. Anergic T cells exhibit defective activation of ERK and JNK (16). Recently, we proposed the nonreceptor tyrosine kinase, Pyk2H, as a key regulator of the JNK pathway leading to IL-2 production by Jurkat cells (17). However, the molecular mechanisms underlying the differential regulation of MAPKs, which determine the T cell fate, still remain elusive.

Cas-L/HEF1 functions in TCR and beta 1-integrin costimulation-mediated induction of cell migration and activation (18, 19). HEF1 belongs to the Cas family of docking proteins consisting of an SH3 domain, substrate domain, and Src family kinase-binding domain (20, 21). The substrate domain includes numerous tyrosine phosphorylation motifs that serve as binding sites for CrkL when phosphorylated by Src family kinase(s) in TCR-mediated signaling (22). Binding of CrkL to HEF1 induces the recruitment of downstream effectors to the HEF1 sites. Two potent CrkL effectors in T cells, C3G and DOCK2, activate the small GTPases Rap1 and Rac, respectively (23-25). This activation further controls cell adhesion and gene expression (26, 27).

In our previous study, we identified Chat as a Cas/HEF1-associated adaptor protein (28). Chat consists of an N-terminal SH2 domain, a C-terminal Cas/HEF1 association domain, and a central serine/proline-rich region containing four potential ERK phosphorylation sites. Indeed, Chat is phosphorylated by ERK when stimulated with epidermal growth factor or nerve growth factor. Overexpression of Chat induces up-regulation of JNK in COS7 cells. Another group has reported the cDNA cloning of NSP3, the human ortholog of Chat (29). Association of the NSP3 relative, NSP1, with tyrosine kinase receptors of the epidermal growth factor or insulin has been demonstrated (29). Chat also shares the most C-terminal sequence with SHEP1, which binds through its SH2 domain to a tyrosine-phosphorylated motif of Eph receptors (30). These data indicate that Chat family proteins are implicated in the signaling pathways of tyrosine kinases and MAPKs.

We have also described a 115-kDa Chat isoform, which is expressed primarily in hematopoietic cells and forms a complex with HEF1 (28). In this study, we report the molecular cloning of the hematopoietic Chat isoform, Chat-H. Jurkat transfectant cells overexpressing Chat-H show a marked up-regulation of IL-2 production when stimulated with a concurrent ligation of TCR and CD28. IL-2 synthesis is suppressed significantly in cells overexpressing the C-terminal deletion mutant of Chat-H. The activation of JNK in these transfectants is well synchronized with the IL-2 production. Chat-H also promotes the phosphorylation of its tyrosine 402, an intermediate of the JNK activation. Taken together, we propose a role for Chat-H as a positive regulator of TCR signaling in Jurkat cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies-- Anti-Chat SH and anti-Chat CT polyclonal antibodies that recognize both Chat and Chat-H were raised as described in our previous work (28). Anti-human CD3 monoclonal antibody (OKT3) was obtained from the American Type Culture Collection, and anti-human CD28 (CD28.2) was from Immunotech. Anti-Pyk2 (N-19) and anti-Pyk2 (C-19) were purchased from Santa Cruz. Anti-phosphotyrosine 402 Pyk2 was from BIOSOURCE. Anti-FLAG (M2) was purchased from Sigma. Anti-phosphotyrosine (4G10) was from Upstate Biotechnology Inc. Antibodies detecting the active form of ERK, JNK, or p38 MAPK were obtained from Promega Corp., and anti-ERK, anti-JNK, and anti-p38 MAPK were from Santa Cruz.

cDNA Cloning and Establishment of Stable Transfectants-- Mouse Chat-H cDNA was isolated from a mouse spleen lambda ZAP II cDNA library (Stratagene) by hybridization screening using the mouse Chat cDNA (GenBank AB030442) probe, followed by nucleotide sequencing. N-terminally FLAG-tagged expression plasmids of Chat-H and its variants, Chat-H-R238K (the SH2 domain arginine 238 was mutated to lysine), Chat-H-Delta MAPK (amino acid residues 324-456 including four MAPK phosphorylation sites were deleted), or Chat-H-Delta CT (C-terminal 83 amino acid residues essential for Cas/HEF1 association were deleted) were constructed as described (28); a schematic representation is depicted in Fig. 2A. The human acute T cell leukemia Jurkat clone E6-1 was obtained from the American Type Culture Collection. Jurkat cells were transfected with the expression plasmid together with pcDNA3.1-Hygro by electroporation (17). The transfectants were selected by 250 µg/ml hygromycin B (Wako Chemicals). The expressed protein level of each hygromycin-resistant clone was examined by immunoblot analysis against the FLAG tag. The expression levels of CD3 and CD28 were determined by flow cytometry as described previously (17). The clones expressing FLAG-tagged Chat-H mutants with amounts of CD3 and CD28 equivalent to those of parental Jurkat cells transfected with pcDNA3.1-Hygro vector alone were selected for the following analyses. Established clones were maintained in 250 µg/ml hygromycin B-containing medium.

Cell Stimulation and Preparation of Cell Lysates-- Jurkat cells (5 × 106-107 cells) were serum starved for 4-6 h to become "resting" cells and then were treated on ice for 15 min with a saturating concentration (10 µg/ml) of OKT3 and/or CD28.2 monoclonal antibodies. Goat anti-mouse IgG (10 µg/ml, Cappel) was added to the cell suspensions to cross-link CD3 and/or CD28 on the cells. The cells were then immediately placed at 37 °C for the indicated time periods. After the desired time point, the cells were lysed in lysis buffer (1% Triton X-100, 25 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 10 mM beta -glycerophosphate, 10 mM pyrophosphate, 100 units/ml aprotinin, 10 µg/ml leupeptin, 25 µM p-nitrophenyl p'-guanidinobenzoate, 1 mM phenylmethylsulfonyl fluoride, 10 mM iodoacetamide) for 30 min at 4 °C. For treatment with a MAPK inhibitor, Jurkat cells were incubated with 50 µM PD98059 or a control solvent (dimethyl sulfoxide) for 30 min at 37 °C, washed, and then stimulated with anti-CD3.

Immunoprecipitation and Immunoblotting-- Immunoprecipitation was carried out by using protein G-Sepharose 4B (Amersham Biosciences) as described above (17). Alkaline phosphatase treatment of immunoprecipitates was described previously (31). For in vitro phosphorylation by active ERK, the immunoprecipitates were washed three times with ERK buffer (50 mM Hepes, pH 7.5, 1 mM MgCl2, 1 mM dithiothreitol) followed by resuspension in ERK buffer containing 100 units of recombinant active ERK (Calbiochem) and 50 µM ATP. After a 1-h incubation at 30 °C, samples were treated with or without alkaline phosphatase and eluted by SDS sample buffer. Immunobotting was performed by the Renaissance enhanced chemiluminescence detection system (PerkinElmer Life Sciences) with a polyvinylidene difluoride membrane (Millipore) as described (17).

Determination of ERK, JNK, and p38 MAP Kinase Activities-- The activated state of MAPKs (ERK, JNK, and p38 MAPK) was determined by immunoblotting using polyclonal antibodies that recognize the dually phosphorylated, active form of ERK, JNK, or p38 MAPK. To normalize the amount of loaded samples, the blots were reprobed with anti-ERK, anti-JNK, or anti-p38 MAPK antibodies. JNK activity was also determined by a solid phase kinase assay using glutathione S-transferase (GST)-c-Jun1-79 (Santa Cruz) and glutathione-Sepharose 4B (Amersham Biosciences) as described (17).

IL-2 Assay-- Jurkat transfectants (2 × 106 cells) were stimulated with either monoclonal antibodies OKT3 and CD28.2 cross-linked by goat anti-mouse IgG or with 10 ng/ml phorbol 12-myristate 13-acetate (Sigma) and 1 µg/ml calcium ionophore (A23187; Calbiochem), as described above (17). After a 24-h incubation, the concentration of IL-2 secreted in the culture supernatant was measured by using human IL-2 enzyme-linked immunosorbent assay kit (Endogen Inc.) according to the manufacturer's instructions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Hematopoietic Cell-specific Chat-H cDNA-- Recently, we identified a novel adaptor protein, Cas/HEF1-associated signal transducer, Chat (28). Chat is expressed in a wide range of tissues with an apparent molecular mass of 78 kDa. Interestingly, a 115-kDa Chat isoform is detected in hematopoietic tissues by using anti-Chat antibodies. Because it is expressed exclusively in hematopoietic cells, we tentatively named this protein Chat-H, a hematopoietic cell-specific Chat. In this study, we isolated a cDNA encoding Chat-H from a mouse spleen cDNA library. Chat-H is encoded by an mRNA isoform that shares most of the 3'-sequence with Chat. The unique 5'-sequence implies differential initiation and splicing of the Chat-H transcript in hematopoietic cells. The Chat-H cDNA sequence is identical to that of SHEP1, reported as an activated Eph receptor-binding protein (30). Chat-H consists of 854 amino acid residues; the molecular mass ~94 kDa (Fig. 1). However, when the Chat-H mRNA was expressed ectopically in 293T cells, the translated product showed an apparent molecular mass of around 115 kDa on SDS-PAGE as observed in hematopoietic tissues (data not shown). The N-terminal amino acid sequence specific for Chat-H (amino acid residues 1-166) does not show any significant similarity to other known protein sequences.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 1.   Primary structure of Chat-H. The amino acid sequence of Chat-H deduced from the nucleotide sequence of mouse Chat-H cDNA is shown. The SH2 domain sequence is underlined. MAPK phosphorylation consensus sites are shown by double underlines. The region that corresponds to the Cas/HEF1 association domain is indicated on the left side of the sequence. The junction site between the N-terminal Chat-H-specific sequence and Chat/Chat-H common region is marked with an arrowhead.

Establishment of Jurkat Clones Expressing Chat-H Variants-- To investigate the role of Chat-H in T cell activation, we established Jurkat transfectants overexpressing Chat-H or its mutants (Fig. 2A). An SH2 domain mutant of Chat-H, Chat-H-R238K, was engineered by replacing a conserved arginine with lysine. The loss of function was verified by its abrogated binding to tyrosine-phosphorylated EphA4 in 293T cell expression system (data not shown). In Chat-H-Delta MAPK, the central region of Chat-H consisting of four ERK phosphorylation consensus sites was deleted. Based on our previous observation, the deletion of the Chat C-terminal 83 amino acid residues is enough to abolish its Cas binding activity (28). Therefore, we constructed Chat-H-Delta CT; the analogous region was deleted. Impaired interaction between Chat-H-Delta CT and HEF1 was confirmed by a coimmunoprecipitation assay (data not shown). The Jurkat clones expressing these Chat-H mutants were screened by immunoblotting as shown in Fig. 2B. The transfectants, showing an 8-10-fold expression level of Chat-H variants over the endogenous level, were selected for the following functional analyses. We also chose the clones with similar expression levels of both CD3 and CD28 to the control cells and established three to four independent clones expressing each Chat-H-related protein (data not shown).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Establishment of Jurkat transfectants overexpressing Chat-H variants. A, schematic representation of Chat-H and its mutants used for establishment of Jurkat transfectants. Full-length Chat-H (ChatH), the SH2 domain point mutant (R238K), deletion mutant of four ERK phosphorylation sites (Delta MAPK), and the C-terminal Cas/HEF1 association domain mutant (Delta CT) are shown. B, expression level of Chat-H variant in each transfectant analyzed by anti- Chat-H immunoblotting.

TCR Engagement Induces ERK-dependent Phosphorylation of Chat-H-- First, we examined whether Chat-H becomes tyrosine phosphorylated in response to TCR stimulation because Chat-H has some potential target motifs for tyrosine kinases. However, we did not detect phosphorylation of these tyrosine residues upon TCR engagement (data not shown). Instead, we found that Chat-H in TCR-stimulated Jurkat cells and mouse splenic T cells exhibits reduced mobility on SDS-PAGE (data not shown). As shown in Fig. 3A, this mobility shift was also observed in TCR-stimulated Chat-H-overexpressing Jurkat cells (JT-ChatH, +Stim.). Pretreatment with a MAPK/ERK kinase inhibitor PD98059 prior to TCR ligation suppressed this mobility change (JT-ChatH, +Stim. +PD). As expected, Chat-H-Delta MAPK, lacking four potential ERK phosphorylation sites, did not show the mobility shift. In addition, alkaline phosphatase treatment of Chat-H reverted the mobility, whereas active ERK induced the mobility change in vitro (Fig. 3B). These results suggest that Chat-H is phosphorylated by ERK upon TCR engagement. This agrees well with our previous observation that ERK mediates Chat phosphorylation in EGF-stimulated PC12 cells (28). There is no difference in HEF1 binding activity between the nonphosphorylated and phosphorylated states of Chat-H (data not shown).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   ERK-mediated phosphorylation of Chat-H induced by TCR activation. A, Jurkat transfectants expressing Chat-H (JT-ChatH) or Chat-H-Delta MAPK (JT-Delta MAPK) were incubated with (+Stim.) or without (-Stim.) anti-CD3 for 3 min. Anti-Chat immunoprecipitates of each stimulated sample were immunoblotted with anti-Chat antibody. To evaluate the effect of a MEK inhibitor on Chat-H phosphorylation, the cells were incubated with 50 µM PD98059 (+PD) for 30 min before stimulation. B, JT-Chat-H cells were incubated with (alpha CD3) or without (None) anti-CD3 for 3 min. For in vitro phosphorylation and dephosphorylation experiments, anti-Chat immunoprecipitates were treated with alkaline phosphatase (+AP), alkaline phosphatase with phosphatase inhibitors (+AP+PI), active ERK (+ERK), or active ERK and alkaline phosphatase (+ERK+AP). The mobility of each Chat-H band was detected by anti-Chat immunoblotting.

Chat-H-overexpressing Jurkat Cells Show Enhanced IL-2 Production after Costimulation of TCR and CD28-- Next, we assessed the IL-2 production level by Jurkat transfectants after costimulation of TCR and CD28 (Fig. 4). The IL-2 concentration in the culture supernatant of Chat-H-overexpressing transfectants (JT-ChatH) was increased up to 4-fold compared with that of control transfectants (JT-Vector). Chat-H-Delta MAPK also enhanced IL-2 production although the impact was significantly weaker than that of Chat-H (p < 0.05). This enhancement was not observed in the transfectant overexpressing the SH2 domain mutant of Chat-H (JT-R238K). Overexpression of Chat-H-Delta CT significantly decreased the IL-2 level (p < 0.01). All of these transfectants produced essentially the same level of IL-2 in response to the combined stimulation with phorbol 12-myristate 13-acetate and A23187, suggesting their equivalent potential in IL-2 synthesis (Fig. 4). Taken together, Chat-H is likely to play a positive role in the coupling signals from TCR and CD28 to IL-2 production, and the interactions via both the SH2 and Cas/HEF1 association domains of Chat-H are essential for the process.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Overexpression of Chat-H promotes IL-2 synthesis after costimulation of TCR and CD28. Jurkat transfectants (2 × 106 cells/well) expressing vector alone (JT-Vector), Chat-H (JT-ChatH), Chat-H-R238K (JT-R238K), Chat-H-Delta MAPK (JT-Delta MAPK), and Chat-H-Delta CT (JT-Delta CT) were incubated with (gray columns) or without (black columns) anti-CD3 and anti-CD28, or phorbol 12-myristate 13-acetate and A23187 (open columns) for 24 h. The concentration of IL-2 in the supernatants was measured by enzyme-linked immunosorbent assay. The values shown are mean values ± S.D. (n = 3).

Chat-H Is Not Involved in the Activation of ERK and p38 MAPK-- The MAPK family comprises three distinct kinases, ERK, JNK, and p38 MAPK. The activation of all three kinases is required for the full activation of T cells (11-15). Therefore, we studied the activation of MAPKs in the Jurkat transfectants upon costimulation of TCR and CD28 and examined the role of Chat-H in IL-2 production by Jurkat cells. We first compared the activation kinetics of ERK and p38 MAPK between Jurkat and Chat-H transfectants upon costimulation (Fig. 5A); the detection was carried out by the antibodies specific for their activated forms. The activation of ERK and p38 MAPK reached its maximum at 5 min and decreased to less than 50% at 20 min. Several independent experiments (data not shown) gave a consensus that there was virtually no difference in the activation kinetics between these transfectants. Next, we examined whether ERK and p38 activation is influenced by the presence of various Chat-H mutants. All of the transfectants were found to be similar in the TCR-induced ERK activation and costimulation-elicited p38 MAPK activation at 5 min (Fig. 5, B and C) and at 20 min (data not shown). Here we show ERK activation data from TCR-stimulated transfectants because TCR-stimulated cells (Fig. 5B) and TCR/CD28-costimulated cells (data not shown) gave essentially the same results. Thus, the activation of ERK and p38 MAPK downstream of the TCR is not affected by the function of Chat-H.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 5.   Chat-H is not involved in the activation of ERK and p38 MAPK downstream of TCR signaling. A, Jurkat transfectants expressing vector alone (JT-Vector) or Chat-H (JT-ChatH) were incubated with anti-CD3 and anti-CD28 for the indicated times. The whole cell lysates were immunoblotted with anti-active ERKs (phospho-ERK) or anti-active p38 MAPK (phospho-p38). B, Jurkat transfectants expressing vector alone (JT-Vector), Chat-H (JT-ChatH), Chat-H-R238K (JT-R238K), Chat-H-Delta MAPK (JT-Delta MAPK), and Chat-H-Delta CT (JT-Delta CT) were incubated with (+Stim.) or without (-Stim.) anti-CD3 for 5 min followed by immunoblotting the cell lysates with anti-active ERKs (upper panel; Phospho-ERK). The expression level of ERKs in these cells is shown (lower panel; ERK1, ERK2). C, the same transfectants used in B were costimulated with (+Stim.) or without (-Stim.) anti-CD3 and anti-CD28 for 5 min, then immunoblotted with anti-active p38 MAPK (upper panel; Phospho-p38). These transfectants express similar amounts of p38 MAPK (lower panel; p38 MAPK).

Chat-H Is Essential for the Activation of JNK upon Costimulation of TCR and CD28-- We next addressed the activation of another MAPK, JNK, in these transfectants. After concurrent ligation of TCR and CD28, JNK activation estimated by activated JNK-specific antibody was promoted significantly in Chat-H-overexpressing cells compared with the control Jurkat cells (data not shown). To quantify the JNK activation level in various transfectants, we employed a solid phase JNK assay. The JNK activity in JT-Chat-H cells was 5-8-fold higher at 10-40 min after stimulation than those in the Jurkat control (Fig. 6A). As shown in Fig. 6B, the Jurkat transfectants overexpressing Chat-H and Chat-H-Delta MAPK exhibited 3-7-fold higher levels of JNK activity over that of the control cells. In contrast, the JNK activation level of JT-Delta CT was reduced to 30-40% of the controls. The JT-R238K showed almost the control level of JNK activity. The degrees of JNK activation in different Jurkat transfectants agree well with their IL-2 production levels (Figs. 4 and 6B). This strongly suggests the possible augmentation of IL-2 production by Chat-H via up-regulation of the JNK activity.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 6.   Chat-H overexpression enhances JNK activation upon costimulation of TCR and CD28. A, Jurkat transfectants expressing vector alone (JT-Vector) and Chat-H (JT-ChatH) were stimulated with anti-CD3 and anti-CD28 for the indicated times, and the lysates were subjected to a solid phase JNK assay. The activity of endogenous JNK pulled down with GST-c-Jun1-79 was evaluated by an autoradiogram of 32P-labeled GST-c-Jun (Phospho-GST-c-Jun). B, Jurkat transfectants expressing vector alone (JT-Vector), Chat-H (JT-ChatH), Chat-H-R238K (JT-R238K), Chat-H-Delta MAPK (JT-Delta MAPK), and Chat-H-Delta CT (JT-Delta CT) were incubated with (+Stim.) or without (-Stim.) anti-CD3 and anti-CD28 for 5 min followed by the JNK assay described above. Relative JNK activities are indicated below.

Chat-H Forms a Complex with Pyk2H and Enhances Phosphorylation of Its Tyrosine 402-- To reveal the mechanism underlying the JNK activation by Chat-H, we examined the effect of Chat-H expression on the tyrosine phosphorylation state of several TCR signal-related molecules. Vav, SLP-76, LAT, and protein kinase Ctheta are tyrosine phosphorylated upon TCR stimulation and implicated in the activation of MAPKs (4-8, 11). However, we did not detect significant alterations in their phosphorylation levels between the control and Chat-H-overexpressing cells (data not shown). Tyrosine phosphorylation levels of Lck, ZAP-70, Fyn, phospholipase C-gamma , and phosphatidylinositol 3-kinase also did not show any significant changes (data not shown).

Nonreceptor tyrosine kinase Pyk2, highly expressed in cells of the hematopoietic lineage and in the central nervous system, is proposed as a key regulator of the JNK signaling pathway in various cellular responses (32-34). We demonstrated recently that Pyk2H, an alternatively spliced isoform of Pyk2, is involved in JNK activation in T cells (17). We further found that the phosphorylation of Pyk2H tyrosine 402 is crucial for the JNK activation; this is also verified in a different system, i.e. angiotensin II signaling in smooth muscle cells (35). As shown in Fig. 7, A and B, anti-Pyk2H immunoprecipitates from the lysates of JT-Pyk2H included a significant amount of Chat-H, and anti-Chat-H-precipitates from JT-Chat-H contained Pyk2H. This coprecipitating activity was abolished in JT-Delta CT, suggesting a HEF1-mediated interaction between Chat-H and Pyk2H. Neither tyrosine 402 phosphorylation of Pyk2H nor ERK-dependent Chat-H phosphorylation induced by TCR activation influenced the extent of the Chat-H-Pyk2H interaction. Intriguingly, overexpression of Chat-H increased the phosphorylation level of Pyk2H tyrosine 402 at about 5-fold over the control upon costimulation of TCR and CD28, whereas Chat-H-Delta CT overexpression decreased it (Fig. 7C). These data suggest that Chat-H and Pyk2H may function together in the integration of costimulatory signals for JNK activation.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 7.   Chat-H functionally interacts with Pyk2H in T cells. A, Jurkat transfectants expressing Chat-H (JT-ChatH) or Chat-H-Delta CT (JT-Delta CT) were incubated with (+Stim.) or without (-Stim.) anti-CD3. Cell lysates were immunoprecipitated with anti-Chat-H (ChatH) or control rabbit IgG (Rab.IgG) followed by immunoblotting with anti-Pyk2H (left panel) or antibody specific for phosphotyrosine 402 of Pyk2H (right panel). B, upper panel, Pyk2H-expressing Jurkat transfectant (JT-Pyk2H) was stimulated with anti-CD3. The amount of Chat-H in anti-Pyk2H immunocomplex (Pyk2H) or its control (Rab.IgG) was examined as in A. Lower panel, the same lysates were immunoblotted with anti-Chat-H. C, Jurkat transfectants expressing vector alone (JT-Vector), Chat-H (JT-ChatH), or Chat-H-Delta CT (JT-Delta CT) were incubated with (+Stim.) or without (-Stim.) anti-CD3 and anti-CD28 followed by anti-Pyk2H immunoprecipitation. The immunoprecipitates were immunoblotted with anti-phosphotyrosine 402 Pyk2H. The numbers under the panel represent the relative phosphorylation level of Pyk2H tyrosine 402.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recently, we identified a novel adaptor protein, Chat, which forms a complex with Cas family docking proteins. We have also described a Chat isoform, Chat-H, abundantly expressed in hematopoietic cells. In the present study, we report the molecular cloning of the Chat-H cDNA. Chat-H is encoded by a mRNA isoform that shares most of the 3'-sequence with Chat. In other words, Chat-H has an extra N-terminal domain absent in Chat. Chat-H is associated with tyrosine-phosphorylated HEF1 in both splenic T cells and thymocytes (Ref. 28 and data not shown), suggesting a possible interplay between Chat-H and HEF1 in T cell development. By using various Jurkat transfectants overexpressing Chat-H or its mutants, we provide evidence that Chat-H is involved in the positive regulation of T cell signaling, which activates IL-2 gene expression: 1) Chat-H overexpression induces a marked enhancement of IL-2 production under costimulation with TCR and CD28; 2) the function of the Chat-H SH2 domain is essential for this up-regulation; and 3) Chat-H-Delta CT, the Cas/HEF1 association domain mutant, shows a dominant negative effect on the IL-2 production. Thus, Chat-H is likely to play a key role in coupling costimulatory signals to IL-2 gene expression collaborating with HEF1 and unknown target(s) of its SH2 domain.

The activation of ERK, JNK, and p38 MAPK is required for adequate induction of IL-2 synthesis in T cells (11-15). Indeed, the enzymatic activities of ERK and JNK are reduced after costimulation of TCR and CD28 in murine anergic T cells (16). These data suggest the close correlation between the activities of the MAPK superfamily and T cell activation. The identification of the signaling components, which integrate costimulatory signals for the differential activation of MAPKs, is a key for clarifying T cell fate determination. Intriguingly, we found that the activation level of JNK, but not of ERK or p38, is greatly augmented in response to the costimulation in Jurkat transfectants overexpressing Chat-H. These cells also exhibit a dramatic increase in their IL-2 production level. In addition, we demonstrated the importance of Chat-H-HEF1-interaction in both the up-regulation of JNK pathway and IL-2 production. Because the members of CrkL-DOCK2-Rac pathway, downstream of HEF1 in T cells, are implicated in JNK activation and IL-2 gene expression (24, 25, 27), it is plausible that Chat-H·HEF1 complexes participate in the positive regulation of IL-2 synthesis via activation of the JNK pathway.

Pyk2H has been shown to up-regulate JNK activation and subsequent IL-2 production after costimulation of TCR and CD28 (17). This process is mediated by phosphorylation of Pyk2H tyrosine 402. Interestingly, Chat-H was found to interact with Pyk2H in a phosphorylation-independent manner, and overexpression of Chat-H further enhances the tyrosine 402 phosphorylation of Pyk2H upon costimulation. Both activities of Chat-H require the functional Cas/HEF1 association domain. This implicates HEF1 in the connection because of its capability to interact with Chat-H and Pyk2H discretely (Refs. 28 and 34 and data not shown). These findings suggest that molecular networks involving Chat-H, HEF1, and Pyk2H may function as a modulator of costimulatory signals to induce efficient T cell activation.

Tyrosine kinases and adaptor proteins play crucial roles in diverse immune cell signaling pathways (4-8). Our data clearly indicate the functional requirement of the Chat-H SH2 domain in the Chat-H-mediated up-regulation of JNK activation and IL-2 synthesis after costimulation. However, Chat-H SH2 domain target(s) responsible for the augmentation of these T cell responses have not yet been identified. Fascinatingly, Chat-H is identical to SHEP1, which binds to activated Eph receptors via its SH2 domain (30). Eph receptor tyrosine kinases function as receptors for ephrins, and the ephrin-Eph system is implicated in a wide range of intercellular communications (36, 37). However, little is known about the role of the ephrin-Eph system in hematopoietic cells. It is very intriguing to assess whether the ephrin-Eph system is involved in T cell activation and differentiation.

Chat-H is phosphorylated by ERK upon TCR stimulation. This raises the possibility that ERK regulates Chat-H function. Chat-H promotes both JNK activation and IL-2 production in the absence of four ERK phosphorylation sites, although the latter activity shows an apparent reduction. It is possible that there is a subordinate route besides the JNK pathway for the enhancement of the IL-2 gene expression downstream of Chat-H. Identification of effector protein(s) whose function is controlled by ERK-mediated Chat-H phosphorylation will provide some insights into its significance in the TCR signaling.

In this report, we illuminated the positive regulatory role of a novel hematopoietic adaptor protein Chat-H in the T cell activation. We also revealed that interactions via its domain structures are crucial for the up-regulation of costimulatory signals. Further investigations on the molecular mechanism of signal integration by Chat-H and in vivo studies using transgenic mice will be the next approaches to understanding the physiological function of Chat-H in the T cell fate determination.

    ACKNOWLEDGEMENTS

We thank D. J. Webb, K. Momotani, R. B. Riggins, and A. H. Bouton for critical reading of the manuscript. We also thank the members of Division of Biochemistry and Cellular Biology, National Institute of Neuroscience for helpful discussions and technical advice.

    FOOTNOTES

* This work was supported in part by a grant for cancer cell biology from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AB043953.

Recipients of a domestic research fellowship from the Japan Science and Technology Corporation.

** To whom correspondence may be addressed: Division of Cellular Proteomics, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Tel.: 81-3-5449-5314; Fax: 81-3-5449-5314; E-mail: katagiri@ims.u-tokyo.ac.jp or hattoris{at}ims.u-tokyo.ac.jp.

Published, JBC Papers in Press, December 14, 2002, DOI 10.1074/jbc.M207942200

    ABBREVIATIONS

The abbreviations used are: TCR, T cell receptor; Chat, Cas/HEF1-associated signal transducer; Chat-H, hematopoietic isoform of Chat; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; IL-2, interleukin-2; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; SH domain, Src homology domain.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Paul, W. E., and Seder, R. A. (1994) Cell 76, 241-251[Medline] [Order article via Infotrieve]
2. Woods, M. L., and Shimizu, Y. (2001) J. Leukocyte Biol. 69, 874-880[Abstract/Free Full Text]
3. Serrador, J. M., Nieto, M., and Sánchez-Madrid, F. (1999) Trends Cell Biol. 9, 228-232[CrossRef][Medline] [Order article via Infotrieve]
4. Qian, D., and Weiss, A. (1997) Curr. Opin. Cell Biol. 9, 205-212[CrossRef][Medline] [Order article via Infotrieve]
5. Werlen, G., and Palmer, E. (2002) Curr. Opin. Immunol. 14, 299-305[CrossRef][Medline] [Order article via Infotrieve]
6. Rudd, C. E. (1999) Cell 96, 5-8[Medline] [Order article via Infotrieve]
7. Leo, A., Wienands, J., Baier, G., Horejsi, V., and Schraven, B. (2002) J. Clin. Invest. 109, 301-309[Free Full Text]
8. Samelson, L. E. (2002) Annu. Rev. Immunol. 20, 371-394[CrossRef][Medline] [Order article via Infotrieve]
9. Frauwirth, K. A., and Thompson, C. B. (2002) J. Clin. Invest. 109, 295-299[Free Full Text]
10. Powell, J., Ragheb, J. A., Kitagawa-Sakakida, S., and Schwartz, R. H. (1998) Immunol. Rev. 165, 287-300[Medline] [Order article via Infotrieve]
11. Rincón, M., Flavell, R. A., and Davis, R. J. (2001) Oncogene 20, 2490-2497[CrossRef][Medline] [Order article via Infotrieve]
12. Franklin, R. A., Tordai, A., Patel, H., Gardner, A. M., Johnson, G. L., and Gelfand, E. W. (1994) J. Clin. Invest. 93, 2134-2140[Medline] [Order article via Infotrieve]
13. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., and Ben-Neriah, Y. (1994) Cell 77, 727-736[Medline] [Order article via Infotrieve]
14. Nishina, H., Bachmann, M., Oliveira-dos-Santos, A. J., Kozieradzki, I., Fischer, K. D., Odermatt, B., Wakeham, A., Shahinian, A., Takimoto, H., Bernstein, A., Mak, T. W., Woodgett, J. R., Ohashi, P. S., and Penninger, J. M. (1997) J. Exp. Med. 186, 941-953[Abstract/Free Full Text]
15. Matsuda, S., Moriguchi, T., Koyasu, S., and Nishida, E. (1998) J. Biol. Chem. 273, 12378-12382[Abstract/Free Full Text]
16. Li, W., Whaley, C. D., Mondine, A., and Mueller, D. L. (1996) Science 271, 1272-1276[Abstract]
17. Katagiri, T., Takahashi, T., Sasaki, T., Nakamura, S., and Hattori, S. (2000) J. Biol. Chem. 275, 19645-19652[Abstract/Free Full Text]
18. Ohashi, Y., Iwata, S., Kamiguchi, K., and Morimoto, C. (1999) J. Immunol. 163, 3727-3734[Abstract/Free Full Text]
19. Kamiguchi, K., Tachibana, K., Iwata, S., Ohashi, Y., and Morimoto, C. (1999) J. Immunol. 163, 563-568[Abstract/Free Full Text]
20. Minegishi, M., Tachibana, K., Sato, T., Iwata, S., Nojima, Y., and Morimoto, C. (1996) J. Exp. Med. 184, 1365-1375[Abstract]
21. Bouton, A. H., Riggins, R. B., and Bruce-Staskal, P. J. (2001) Oncogene 20, 6448-6458[CrossRef][Medline] [Order article via Infotrieve]
22. Kanda, H., Mimura, T., Hamasaki, K., Yamamoto, K., Yazaki, Y., Hirai, H., and Nojima, Y. (1999) Immunology 97, 56-61[CrossRef][Medline] [Order article via Infotrieve]
23. Ohashi, Y., Tachibana, K., Kamiguchi, K., Fujita, H., and Morimoto, C. (1998) J. Biol. Chem. 273, 6446-6451[Abstract/Free Full Text]
24. Nishihara, H., Maeda, M., Oda, A., Tsuda, M., Sawa, H., Nagashima, K., and Tanaka, S. (2002) Blood 100, 3968-3974[Abstract/Free Full Text]
25. Nishihara, H., Maeda, M., Tsuda, M., Makino, Y., Sawa, H., Nagashima, K., and Tanaka, S. (2002) Biochem. Biophys. Res. Commun. 296, 716-720[CrossRef][Medline] [Order article via Infotrieve]
26. Bos, J. L., de Rooij, J., and Reedquist, K. A. (2001) Nat. Rev. Mol. Cell. Biol. 2, 369-377[CrossRef][Medline] [Order article via Infotrieve]
27. Takai, Y., Sasaki, T., and Matozaki, T. (2001) Physiol. Rev. 81, 153-208[Abstract/Free Full Text]
28. Sakakibara, A., and Hattori, S. (2000) J. Biol. Chem. 275, 6404-6410[Abstract/Free Full Text]
29. Lu, Y., Brush, J., and Stewart, T. A. (1999) J. Biol. Chem. 274, 10047-10052[Abstract/Free Full Text]
30. Dodelet, V. C., Pazzagli, C., Zisch, A. H., Hauser, C. A., and Pasquale, E. B. (1999) J. Biol. Chem. 274, 31941-31946[Abstract/Free Full Text]
31. Sakakibara, A., Furuse, M., Saitou, M., Ando-Akatsuka, Y., and Tsukita, S. (1997) J. Cell Biol. 137, 1393-1401[Abstract/Free Full Text]
32. Tokiwa, G., Dikic, I., Lev, S., and Schlessinger, J. (1996) Science 273, 792-794[Abstract]
33. Yu, H., Li, X., Marchetto, G. S., Dy, R., Hunter, D., Calvo, B., Dawson, T. L., Wilm, M., Anderegg, R. J., Graves, L. M., and Earp, H. S. (1996) J. Biol. Chem. 271, 29993-29998[Abstract/Free Full Text]
34. Avraham, H., Park, S.-Y., Schinkmann, K., and Avraham, S. (2000) Cell. Signal. 12, 123-133[CrossRef][Medline] [Order article via Infotrieve]
35. Frank, G. D., Eguchi, S., Motley, E. D., Sasaki, T., and Inagami, T. (2001) Biochem. Biophys. Res. Commun. 286, 692-696[CrossRef][Medline] [Order article via Infotrieve]
36. Holder, N., and Klein, R. (1999) Development 126, 2033-2044[Abstract/Free Full Text]
37. Schmucker, D., and Zipursky, S. L. (2001) Cell 105, 701-704[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.